7TM Pharma's new first-in-class anti-obesity drug completes Phase I/II clinical studies(03/22/2006) 7TM Pharma announced positive results from its clinical Phase I/II study with its lead compound TM30338, a dual Y2-Y4 receptor agonist developed for the treatment of obesity and related diseases. Both the primary and secondary objective of the study ...
7TM Pharma signs research agreement with Procter & Gamble(04/14/2005) 7TM Pharma announced an agreement with Procter & Gamble Pharmaceuticals, Inc. (P&GP), a subsidiary of The Procter & Gamble Company, under which the parties will undertake a joint research program within therapeutic angiogenesis with the aim of ...
Top
